



1330 Connecticut Avenue, NW  
Washington, DC 20036  
TEL: 202.429.6284  
FAX: 202.429.3902  
hfox@steptoe.com

**Areas of Practice**

Clean Energy Technology

Intellectual Property

IP Due Diligence

IP Government Contracts

IP Licensing

IP Litigation

Patent

Patent Counseling,  
Clearance, & Prosecution

Patent Litigation

Patent: Business Methods

Patent: Chemistry

Patent: Materials Science

Patent: Mechanical

Patent: Medical Devices

Patent: Nanotechnologies

Patent: Pharmaceuticals &  
Biotechnology

Section 337/ITC Litigation

Trademark

Trademark Litigation

**Education**

Boston University School  
of Law, J.D., 1999

Massachusetts Institute of  
Technology, Ph.D.,

**Harold H. Fox**

Harold H. Fox is a partner in the Washington office of Steptoe & Johnson LLP, where he is a member of the Intellectual Property group.

Dr. Fox's intellectual property practice covers strategic intellectual property counseling, including strategic patent advice to clients in the context of patent enforcement actions, patent portfolio development, product life-cycle management and intellectual property portfolio evaluations. He is experienced in all areas of chemistry, biotechnology, pharmaceuticals, biologics, nanotechnology, physics, chemical engineering, mechanical engineering, medical devices, business methods, and materials science. Additionally, he has addressed intellectual property issues in government contracts and handled trademark and domain name issues.

He regularly assists clients in patent drafting and prosecution, patent interferences, patent infringement and validity studies, client counseling projects, advising on patent litigation strategy, and handling due-diligence investigations. Specifically, Dr. Fox regularly renders validity/invalidity opinions, infringement/noninfringement opinions, and freedom-to-operate opinions, drafts patent applications, licenses, research agreements, development agreements, and licenses, and conducts due-diligence, and pre-litigation studies. His patent litigation experiences include advising and representing clients in US District Court litigation as well as Section 337 patent infringement investigations before the US International Trade Commission.

Dr. Fox has published numerous research articles in the fields of inorganic chemistry, physical chemistry, organic chemistry, organometallic chemistry, catalysis, polymer chemistry, materials chemistry, electrochemistry, nonlinear optics, glass and ceramic materials, conjugated/conductive polymers, and theoretical chemistry in publications such as *Science*, the *Journal of the American Chemical Society*, the *Journal of Organic Chemistry*, *Macromolecules*, and *Organometallics*.

**Noteworthy**

- Named one of the top 50 under 45 by *IP Law & Business* for 2008

**Select Seminars & Events**

"Intellectual Property Case Law Update and Resulting Litigation Issues",  
October 8, 2008, *Third Annual Biotech Institute and Regional CLE Workshop*

Nanotechnology in Food and Agriculture, June 7, 2006

Harold Fox Speaks at PAT Conference, June 27, 2005

Chemistry, 1993

Massachusetts Institute of  
Technology, B.S.,  
Chemistry, 1988

**Bar & Court Admissions**

District of Columbia

Maryland

US Patent and Trademark  
Office

**Harold H. Fox**

**Selected Publications**

Intellectual Property Advisory - Patentability of Methods Generally Upheld  
June 29, 2010

Intellectual Property Advisory - Induced Infringement Can Be Shown Without  
Direct Evidence that Accused Infringer Knew of Asserted Patent  
February 15, 2010

Intellectual Property Advisory - Federal Circuit Affirms Patent Term  
Adjustment Calculation  
January 8, 2010

Intellectual Property Advisory - Recent Bills (Re)Introduced in Congress  
Directed to Pharmaceutical Companies  
March 30, 2009

Intellectual Property Advisory - FDA Denies 30-Month Stay of Approval of  
Certain ANDAs Under the QI-Act  
March 23, 2009

Intellectual Property Advisory - Amendments to Chinese Patent Law Affecting  
Pharmaceutical and Biotech Companies  
February 16, 2009

Intellectual Property Advisory - New Requirements for Submission of  
Bioequivalence Data for Generic Drug Applications  
January 28, 2009

**Professional Affiliations**

American Chemical Society